focus -WSS

focus

author：focus 2025-09-29 22:37:12 - browse：6579

ESMO signage in Madrid. — At ESMO 2023, antibody-drug conjugates were featured prominently. Andrew Joseph/STAT

MADRID — If you had to pinpoint one subject that stood out at this year’s European Society for Medical Oncology meeting, a massive conference with thousands of people from 140-some countries and 2,500 studies presented, it would be a burgeoning type of cancer treatment called antibody-drug conjugates.

The conference opened to the news that Merck had signed one of the biggest licensing deals in industry history — worth up to $22 billion — to partner on three of the compounds from ADC specialist Daiichi Sankyo. GSK followed up with an ADC licensing announcement of its own (if a much smaller one). Multiple ADC studies were presented at the meeting’s top sessions. ADCs were, in short, the belle of the cancer research ball.

The thing is, ADCs are actually quite an old approach.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Can sheer will power keep patients alive in their dying hours?

knowledge

WSS

Can sheer will power keep patients alive in their dying hours?

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Hospitals owned by private equity see complications spike 25%

Mayo Clinic plans $5B tech

David Ricks of Eli Lilly: best biopharma CEO of 2023

CDC director unscathed in first congressional testimony

Wikipedia

focus

focus

In age of alternative facts, a scholarly course on calling out crap

30 years of 'Listening to Prozac'

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

What STAT readers think about the FDA and patient advocacy

Alkermes shareholders re

Rep. Raul Ruiz on the physician shortage and more

Drug repurposing or repositioning? The language matters

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

DIEP, the 'gold standard' of breast reconstruction, is under threat

In Spain, a hospital brews its own CAR

focus

Fetal surgery at risk from Dobbs and new abortion restrictions

CRISPR gene editing developments we’re watching in 2024

David Ricks of Eli Lilly: best biopharma CEO of 2023

J&J to emphasize cancer drugs, stop much of its vaccine research

Grail spinoff by Illumina should end disastrous merger attempt

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

knowledge

explore

hotspot

Wikipedia